Physician profile
Adeeb Thomas
NPI 1568443786
$563.66
in general payments reported to CMS, 2019-2025
11 companies · $93.90 in 2025
The $93.90 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $12.26 · 2021: $95.80 · 2022: $202 · 2023: $23.10 · 2024: $21.19 · 2025: $93.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $252.84 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.44 | 2019 | |
| Novo Nordisk INC | $51.39 | 2025 | Wegovy |
| Ucb, INC. | $42.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.31 | 2024-2025 | Austedo Xr, Austedo Xr |
| Currax Pharmaceuticals LLC | $27.78 | 2021 | |
| Ardelyx, INC. | $23.39 | 2025 | Ibsrela |
| Sk Life Science, INC. | $23.10 | 2023 | |
| Neurocrine Biosciences, INC. | $16.96 | 2022 | |
| Acadia Pharmaceuticals INC | $16.03 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeeb Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.